Publications
2025
Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics
Bediako-Kakari, P., Monyo, M., Atoyebi, S., & Olagunju, A. (2025). Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics. npj Women's Health, 3(1). doi:10.1038/s44294-025-00077-9
Modeling tail-phase PK from early pregnancy to postpartum and fetal exposure to long-acting CAB-RPV
Atoyebi, S., Waitt, C., & Olagunju, A. (2025). Modeling tail-phase PK from early pregnancy to postpartum and fetal exposure to long-acting CAB-RPV. In Conference on Retroviruses and Opportunistic Infections. San Francisco, California, USA: CROI Foundation/IAS–USA. Retrieved from https://www.croiconference.org/croi-2025-resources/
2024
Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy
Atoyebi, S., Montanha, M. C., Nakijoba, R., Orrell, C., Mugerwa, H., Siccardi, M., . . . Waitt, C. (2024). Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy. CPT: Pharmacometrics & Systems Pharmacology. doi:10.1002/psp4.13268
USING COMPUTATIONAL MODELS TO AID OPTIMISATION OF THE PHARMACOTHERAPY OF SELECTED ANTIRETROVIRALS IN COMPLEX POPULATIONS
Atoyebi, S. (2024, May). USING COMPUTATIONAL MODELS TO AID OPTIMISATION OF THE PHARMACOTHERAPY OF SELECTED ANTIRETROVIRALS IN COMPLEX POPULATIONS.
Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy
Atoyebi, S., Bunglawala, F., Cottura, N., Grañana-Castillo, S., Montanha, M., Olagunju, A., . . . Waitt, C. (2024). Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. British Journal of Clinical Pharmacology. doi:10.1111/bcp.16006
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using LC-MS/MS
2023
PA-727 Physiologically-based pharmacokinetic modelling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy
Atoyebi, S., Montanha, M. C., Najjemba, L., Orrell, C., Jennings, L., Mugerwa, H., . . . Waitt, C. (2023). PA-727 Physiologically-based pharmacokinetic modelling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy. In Abstracts of Poster and e-Poster Presentations (pp. A114.2-A114). BMJ Publishing Group Ltd. doi:10.1136/bmjgh-2023-edc.279
2022
Physiologically-based pharmacokinetic modelling of long-acting cabotegravir in pregnancy suggests that dose adjustment might not be necessary
Atoyebi, S., Cottura, N., Bunglawala, F., Camotti-Montanha, M., Siccardi, M., & Waitt, C. (2022, September 19). Physiologically-based pharmacokinetic modelling of long-acting cabotegravir in pregnancy suggests that dose adjustment might not be necessary. In Reviews in Antiviral Therapy & Infectious Diseases 2022 Vol. 8 (pp. 1-37). Barcelona, Spain.
PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY
Atoyebi, S., Bunglawala, F., Cottura, N., Camotti-Montanha, M., Siccardi, M., & Waitt, C. (2022). PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY. In Fazila Bunglawala. Conference on Retroviruses and Opportunistic Infections.
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2
2021
Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester
Shenkoya, B., Atoyebi, S., Eniayewu, I., Akinloye, A., & Olagunju, A. (2021). Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester. FRONTIERS IN PEDIATRICS, 9. doi:10.3389/fped.2021.734122
2019
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies
Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068
2018
Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 1(16). doi:10.12688/aasopenres.12860.1
Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
Olagunju, A., Rajoli, R., Atoyebi, S., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. doi:10.12688/aasopenres.12860.1
2016
ISOLATION OF NOVEL PARA-PENTYL PHENYL BENZOATE FROM <i>MONDIA WHITEI</i>.(HOOK. F.) SKEELS (PERIPLOCACEAE), ITS STRUCTURE, SYNTHESIS AND NEUROPHARMACOLOGICAL EVALUATION
Taiwo, B. J., Osasan, J. Y., Olubiyi, O. O., Idris, O. A., Shakir, A. A. M., Elsegood, M. R. J., & Jones, R. C. F. (2017). ISOLATION OF NOVEL PARA-PENTYL PHENYL BENZOATE FROM <i>MONDIA WHITEI</i>.(HOOK. F.) SKEELS (PERIPLOCACEAE), ITS STRUCTURE, SYNTHESIS AND NEUROPHARMACOLOGICAL EVALUATION. AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES, 14(1), 219-230. doi:10.21010/ajtcam.v14i1.24